Targets › SLC29A1
4 programs from 4 companies in 4 trials: 2 Phase 2, 1 Phase 4, 1 Phase 1; Genitourinary, Cardiovascular, Neurology; next expected readout Dec 2026.
Uniporter involved in the facilitative transport of nucleosides and nucleobases, and contributes to maintaining their cellular homeostasis. Functions as a Na(+)-independent transporter. (UniProt, Q99808)
Open in Phaseline: the race on SLC29A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vastra Gotaland Region | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 4 | Takotsubo Syndrome | Dec 2028 |
| Yunfeng Xia | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 2 | Restless Leg Syndrome Due to Uraemia | Dec 2026 |
| Stanford University | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 2 | Hypophosphatemia | May 2027 |
| University of Miami | Abacavir Human immunodeficiency virus type 1 reverse transcriptase inhibitor | SLC29A1 | Phase 1 | High Grade Glioma | Apr 2029 |
Hypophosphatemia (1) Takotsubo Syndrome (1) Restless Leg Syndrome Due to Uraemia (1) High Grade Glioma (1)
small molecule (4)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.